Availability: BPC-157 is not currently orderable from Rebody. This guide covers regulatory status and sourcing risk, not a live offer.
The short answer
In July 2026, FDA's Pharmacy Compounding Advisory Committee voted favorably on both BPC-157 free base and BPC-157 acetate, 8 to 6 with 1 abstention on each. That moves the prescription and compounding question forward. The websites selling BPC-157 as a research chemical are not part of that path, and they are where the real risk sits.
Where the status actually stands
| Question | Where it stands |
|---|---|
| FDA-approved drug | No |
| Bulk substance category | Category 2, flagged for significant safety risk |
| PCAC advisory vote, July 23 2026 | Favorable, 8–6–1 on free base and on acetate |
| Section 503A Bulks List | Not final; the committee advises, FDA decides |
| Legal to buy as a research chemical | Sold that way, outside any medical or pharmacy control |
| Permitted in tested sport | No, on the WADA Prohibited List since 2022 |
What "not FDA approved" does and does not mean
BPC-157 has no FDA approval as a drug, which means no manufacturer has taken it through the trials that establish a dose, an indication, and a safety profile. That is a real gap and it is worth stating plainly.
It is a different statement from illegal. Compounded preparations exist in a separate framework from approved drugs, and the question for BPC-157 has been whether it belongs on the list of bulk substances a 503A pharmacy may compound with. FDA placed it in Category 2, its designation for substances that may present significant safety risk. That placement drew sustained objection from compounding and clinical practitioners, which is why the advisory committee took the question up again.
What the July 2026 advisory vote changed
On July 23, 2026, the Pharmacy Compounding Advisory Committee voted on BPC-157 in both its free base and acetate forms. Each received 8 yes votes, 6 no votes, and 1 abstention.
Two things about that result deserve precision. The vote is favorable, and it is advisory. The committee recommends; FDA makes the final determination about the Section 503A Bulks List. A favorable vote is a meaningful signal about where the regulated path is heading, not a finished rule you can order against today.
Testimony at that meeting also put a real-world exposure record on the table. Dr. Alex Tatem entered more than 16 million doses of compounded BPC-157 into the record, with seven complaints identified across that dataset and no clear attributable safety signal. That is passive complaint data presented by an advocate at an advisory hearing rather than a controlled trial, and it should be read as what it is. It is still a far larger human exposure record than the published literature, and it is the reason the committee's discussion did not track the published-evidence picture alone.
Rebody keeps a live PCAC peptide vote tracker with form-level status as results are verified.
What the published human evidence actually contains
The published record is thin and specific. A 2026 pharmacy review counted three uncontrolled pilot studies with roughly 30 participants combined, which includes a three-day intravenous pilot in two previously exposed adults that measured short-term liver and kidney markers and found no change. A 2025 literature review noted three studies reporting no adverse effects after injection in patients with intra-articular knee pain.
No receptor for BPC-157 has been identified, and validated human pharmacokinetics do not exist. So the mechanism work, which is genuinely detailed, sits entirely in animal and cell models: VEGF receptor signaling and downstream PI3K, ERK1/2, and nitric oxide pathways; focal adhesion kinase and paxillin phosphorylation governing cell migration into damaged tissue; and reductions in tumor necrosis factor alpha, interleukin-6, and interferon gamma with a shift in macrophage activity toward the reparative type.
That combination is unusual. The preclinical detail is strong, the real-world exposure record is large, and the controlled human trial record is close to empty. All three statements are true at once, and any page giving you only one of them is arguing rather than informing.
The gray market is the actual hazard
Because BPC-157 is sold as a research chemical, anyone can buy a vial without a prescription, a clinician, or a pharmacy. That convenience is the problem.
A research-chemical vial carries no verified identity, no verified purity, no verified concentration, and no sterility assurance. You cannot confirm the powder is BPC-157, that the milligram figure on the label matches the contents, or that the vial was filled under conditions that make injection reasonable. Peptide products in particular carry an immunogenicity concern, meaning the immune system can react to the molecule or to impurities alongside it, and purity is exactly what an anonymous vial cannot establish.
This is the distinction that gets lost when a page asks whether BPC-157 is "safe." A compounded preparation from a licensed pharmacy against a prescription, with a certificate of analysis and a beyond-use date, is a different product from a vial shipped by a website that labels it not for human use. Same molecule name, different risk entirely.
Safety questions that stay open regardless of source
Users report local injection-site reactions: redness, swelling, bruising, and pain. Those belong to the route.
One systemic question deserves direct attention with a prescriber. The VEGF and nitric oxide activity that plausibly drives the repair effect also raises questions about dizziness and cardiovascular response, and no human study has characterized either.
Interactions with existing medications and preexisting conditions are unstudied in humans. Pregnancy and breastfeeding, immune conditions, and clotting disorders belong in the same conversation.
Tested athletes have a separate answer
WADA added BPC-157 to its Prohibited List effective in 2022. For anyone subject to testing, that decision is already made, and it does not change based on a prescription, a favorable FDA advisory vote, or off-season use. Check your sport's current list and your governing body's rules directly.
How to read a source on this topic
The regulatory picture moved in July 2026, so publication dates matter more than usual here. An article written before July 23 describes a pending review. An article written after describes a favorable advisory vote that FDA has not finalized. Both can be accurate on their own date and misleading on yours.
Two other tells are worth knowing. A page that describes BPC-157's tendon results without naming the species is describing rat studies. A page that offers to sell you a vial without a prescription is describing the gray market, whatever else it says about safety.
Where Rebody sits
BPC-157 is not orderable from Rebody. Rebody's live catalog runs on prescriptions written after clinician review and filled by licensed pharmacies, and BPC-157 does not currently meet that bar in the United States.
The July vote is a step toward a regulated path rather than the end of one. If FDA places BPC-157 on the 503A Bulks List, the compounding route becomes available and the question changes from whether a legitimate supply exists to whether it is right for a given patient. Until that happens, buying from a research-chemical site is not an early version of that path. It is a different thing wearing the same name.
Questions people ask about BPC-157 legality
Is BPC-157 FDA approved?
No. No manufacturer has taken BPC-157 through the approval process, so there is no FDA-established dose, indication, or safety profile. Approval and compounding eligibility are separate questions, and the compounding question is the one that moved in July 2026.
Why was BPC-157 restricted?
FDA placed it in Category 2 of its bulk drug substances review, the designation for substances that may present significant safety risk, citing limited establishment of purity, efficacy, and safety along with immunogenicity potential. Compounding and clinical practitioners objected, and the advisory committee revisited the question.
Can you get BPC-157 with a prescription right now?
Access has run through clinicians working with compounding pharmacies, and the Category 2 placement constrained that. The July 2026 advisory vote was favorable, but FDA has not issued a final determination, so the compounding path is not settled.
Is BPC-157 a research chemical?
It is sold that way online, which is a marketing and legal posture rather than a description of quality. Research-chemical vials carry no verified identity, purity, concentration, or sterility, and they are typically labeled not for human use.
Is BPC-157 banned in sports?
Yes. WADA added it to the Prohibited List effective in 2022. A prescription does not create an exemption, and out-of-season use is still covered.
What is a category 2 bulk drug substance?
It is FDA's classification for a substance that may present significant safety risk when used in compounding. The classification reflects the agency's risk assessment rather than a finding that the substance is harmful in use.
Does the PCAC vote mean BPC-157 is now legal?
No. The committee advises FDA and the vote was 8–6–1 in favor on each form. FDA decides whether the substance goes on the Section 503A Bulks List, and until it does, the compounding path is not open.
Bottom line
The regulated path for BPC-157 is genuinely moving. A favorable advisory vote on both forms, a 16-million-dose real-world exposure record on the FDA record, and detailed preclinical mechanism work all point the same direction, while the controlled human trials that would settle the question have not been run. None of that describes the vial for sale online without a prescription, which is the one part of this story with a knowable and avoidable risk.
Keep reading
- Reading a BPC-157 Injection Label
- BPC-157 Injection Supplies and Storage
- Reading a TB-500 Injection Label
- BPC-157 Peptides: What the Body Protection Compound Actually Does
Primary sources
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://www.fda.gov/media/193343/download
- https://www.wada-ama.org/en/news/wadas-2022-prohibited-list-now-force
- https://pubmed.ncbi.nlm.nih.gov/40131143/
- https://www.pharmacytimes.com/view/heal-or-harm-body-protective-compound-157-in-the-gray-zone